06:45:59 EDT Fri 14 May 2021
Enter Symbol
or Name

Login ID:

Emerging Markets Report: A Psychedelic Solution to a National Crisis

2021-03-23 07:07 ET - News Release

An Emerging Markets Sponsored Commentary

ORLANDO, Fla., March 23, 2021 (GLOBE NEWSWIRE) -- Today’s featured company is emerging in a new lane of health care that we believe could be revolutionary. Please allow us to introduce Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH).

Let’s start with the Company mission statement:

“MINDCURE is focused on finding new ways to treat the profound distress of a world suffering from a mental health crisis. This is a tremendous opportunity to bring a new category of psychoactive and psychedelic treatments to market.”

It’s a bold statement for sure but unless you’ve had your power out the last year you’ve seen the tremendous amount of new interest in psilocybin and psychedelics specifically for mental health applications.

Here are a few bullets to consider before we discuss what’s novel at MINDCURE.

  • In late June, 40% of U.S. adults reported struggling with mental health or substance use.
  • One in six U.S. youth aged 6-17 experience a mental health disorder each year.
  • Half of all lifetime mental illness begins by age 14, and 75% by age 24.
  • Depression alone costs the nation about $210.5 billion annually.
  • The average delay between onset of mental illness symptoms and treatment is 11 years.
  • Suicide is the second-leading cause of death among people aged 10-34 in the U.S. and the 10th leading cause of death in the U.S.
  • Many people suffer from more than one mental disorder at a given time. In particular, depressive illnesses tend to co-occur with substance abuse and anxiety disorders.
  • More than 70% of youth in the juvenile justice system have a diagnosed mental illness.
  • Transgender adults are nearly 12 times more likely to attempt suicide than the general population.
  • The most common mental illnesses in the U.S. are anxiety disorders, which affect 40 million adults (18.1% of the population).

It’s staggering and we’d imagine everyone reading this note can affirm at least part of the list. The mental health crisis is clear.

This prescient article from Forbes titled “Why the Future of Mental Health Care May Lie in Psychedelics” is compelling. Here’s an important breakout quote:

In just a handful of years, the perception of psychedelics’ brand image among mainstream audiences has rapidly shifted from a dubious party drug to an approachable form of medicine.”

To this end MINDCURE is focused on transforming pain and mental health to “bring people from despair and dependency to hope and healing.”

Their focus lies in three key divisions: direct to consumer products, technology with their iSTRYM and Psycollage platforms, and psychedelic research and drug development.

MINDCURE has put together a compelling story in connection with through their digital therapeutics’ platform and strategic investment in clinics. Combined with psychedelic compound research, they are a unique company in this burgeoning space.

Using big data and technology, MINDCURE is transforming pain treatment and mental health and wellness by investigating the treatment potential of new and combination psychedelic compounds for treatment of multiple disorders.

We will examine these in greater depth as we go forward and in the interim we strongly encourage you to do some due diligence on the company’s website and learn a little more about a Company working to develop a psychedelic solution to a national crisis.

About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

Must Read OTC Markets/SEC policy on stock promotion and investor protection

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

EMC has been paid $225,000 from Sandstone Media, LLC on behalf of Mind Cure Health, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php

Emerging Markets Consulting, LLC
Florida Office
390 North Orange Ave. Suite 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.comWeb: www.emergingmarketsllc.com

© 2021 Canjex Publishing Ltd. All rights reserved.